Vanucizumab
Vanucizumab (RG7221) is a bi-specific monoclonal antibody composed of two different heavy chains and two different light chains. One arm of the antibody binds Angiopoietin-2 (Ang2) and the other is based on bevacizumab (Avastin), binding Vascular Endothelial Growth Factor A (VEGF-A). The antibody is designed to inhibit both VEGF-A and Ang2 simultaneously to offer superior clinical benefit compared to VEGF-A inhibition alone.
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Target | angiopoietin 2 |
| Clinical data | |
| ATC code | none |
| Identifiers | |
| CAS Number | 1448221-05-3 |
| ChemSpider | none |
| Chemical and physical data | |
| Formula | C6529H10033N1733O2038S46 |
| Molar mass | 146.6 kDa |
Vanucizumab (INN) is a humanized monoclonal antibody designed for the treatment of cancer.[1][2]
This drug was developed by Genentech/Roche.
References
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Vanucizumab, American Medical Association.
- ↑ World Health Organization (2014). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 111" (PDF). WHO Drug Information. 28 (2).
This article is issued from Wikipedia - version of the 11/23/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.